Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
Top Cited Papers
Open Access
- 31 July 2020
- Vol. 106 (19), 1503-1511
- https://doi.org/10.1136/heartjnl-2020-317393
Abstract
Background There is uncertainty about the associations of angiotensive enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) drugs with COVID-19 disease. We studied whether patients prescribed these drugs had altered risks of contracting severe COVID-19 disease and receiving associated intensive care unit (ICU) admission. Methods This was a prospective cohort study using routinely collected data from 1205 general practices in England with 8.28 million participants aged 20–99 years. We used Cox proportional hazards models to derive adjusted HRs for exposure to ACE inhibitor and ARB drugs adjusted for sociodemographic factors, concurrent medications and geographical region. The primary outcomes were: (a) COVID-19 RT-PCR diagnosed disease and (b) COVID-19 disease resulting in ICU care. Findings Of 19 486 patients who had COVID-19 disease, 1286 received ICU care. ACE inhibitors were associated with a significantly reduced risk of COVID-19 disease (adjusted HR 0.71, 95% CI 0.67 to 0.74) but no increased risk of ICU care (adjusted HR 0.89, 95% CI 0.75 to 1.06) after adjusting for a wide range of confounders. Adjusted HRs for ARBs were 0.63 (95% CI 0.59 to 0.67) for COVID-19 disease and 1.02 (95% CI 0.83 to 1.25) for ICU care. There were significant interactions between ethnicity and ACE inhibitors and ARBs for COVID-19 disease. The risk of COVID-19 disease associated with ACE inhibitors was higher in Caribbean (adjusted HR 1.05, 95% CI 0.87 to 1.28) and Black African (adjusted HR 1.31, 95% CI 1.08 to 1.59) groups than the white group (adjusted HR 0.66, 95% CI 0.63 to 0.70). A higher risk of COVID-19 with ARBs was seen for Black African (adjusted HR 1.24, 95% CI 0.99 to 1.58) than the white (adjusted HR 0.56, 95% CI 0.52 to 0.62) group. Interpretation ACE inhibitors and ARBs are associated with reduced risks of COVID-19 disease after adjusting for a wide range of variables. Neither ACE inhibitors nor ARBs are associated with significantly increased risks of receiving ICU care. Variations between different ethnic groups raise the possibility of ethnic-specific effects of ACE inhibitors/ARBs on COVID-19 disease susceptibility and severity which deserves further study.Keywords
Funding Information
- Wellcome Trust (204826/Z/16/Z, the Oxford Wellcome Institutional Strategic Suppor)
- the John Fell Oxford University Press Research Fund
- NIHR Biomedical Research Centre, Oxford
- Medical sciences Division, University of Oxford
- Cancer Research UK (Cancer Research UK (CR-UK) grant number C5255/A180)
This publication has 24 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19The New England Journal of Medicine, 2020
- COVID-19 and SmokingNicotine & Tobacco Research, 2020
- Admission patterns and survival from status epilepticus in critical care in the UK: an analysis of the Intensive Care National Audit and Research Centre Case Mix Programme databaseEuropean Journal of Neurology, 2019
- Anticholinergic Drug Exposure and the Risk of DementiaJAMA Internal Medicine, 2019
- Spatial distribution of clinical computer systems in primary care in England in 2016 and implications for primary care electronic medical record databases: a cross-sectional population studyBMJ Open, 2018
- Development and validation of the new ICNARC model for prediction of acute hospital mortality in adult critical careJournal of Critical Care, 2017
- Imputation is beneficial for handling missing data in predictive modelsJournal of Clinical Epidemiology, 2007
- Is Smoking Beneficial for Granulomatous Lung Diseases?American Journal of Respiratory and Critical Care Medicine, 2004
- Nicotine treatment for ulcerative colitisBritish Journal of Clinical Pharmacology, 1999